Cannabis Science Creates A New Policy Advisory Board With Prominent Denver Attorney, Brian Vicente As First Member And Will Expand Its Scientific Advisory Board As Expert Support for The Company Increases From Those Most Knowledgeable About the Importance
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, reports that it has created a new Policy Advisory Board as it receives an unprecedented amount of support from various professionals wanting to advance the Company's development of medical cannabis products. These individuals include attorneys, financial experts, and pharmaceutical manufacturing specialists. Also, the Company is expanding its Scientific Advisory Board to add more members and broaden its focus.
The first member of the new Policy Advisory board is Brian Vicente, Esq., a Denver defense attorney who serves as executive director of Sensible Colorado, the states leading non-profit working for medical marijuana patients and caregivers. He is also the chairman of the Denver Mayor's Marijuana Policy Review Panel and coordinates the Colorado Bar Association's Drug Policy Project. He was awarded the prestigious Gideon award for his free speech advocacy during the 2008 Democratic National Convention.
More professionals will be added who are expert in other relevant fields, such as FDA procedures and state and federal laws. These new additions to the CBIS team will provide the Company with an outstanding expanded base of knowledge to build on.
Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "We have been enormously gratified by the very positive reaction to the company's plans by those who are most familiar with the need for medical cannabis products. The fact that so many prominent experts understand the importance of what we are doing and support our efforts shows that we are on the right path. We are putting together a very powerful team and with their help we will successfully blend the revolutionary power of capitalism with activism moving the company forward."
The formation of the Scientific Advisory Board was announced on August 6th with the appointment of Dr. Mitch Earlywine Ph. D. as its first member and the appointment Dr. Ritchard L. Fishman M.D. was announced on August 18th. With the addition of several prominent scientists and physicians with their knowledge base, the clinical trial focus, product development, and design procedures for submitting products to the FDA can be advanced much faster. These new members will be announced as they formally join our advisory teams.
Richard Cowan, Cannabis Science CFO, added, "I have been very encouraged by the number of experts in corporate finance who have understood the huge economic potential of cannabinoid-based medicines. We are now highly confident that we will achieve the backing that we need to move the company forward."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.